Article Details

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Increased to Hold at Zacks Investment Research

Retrieved on: 2020-12-09 17:15:00

Tags for this article:

Click the tags to see associated articles and topics

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Increased to Hold at Zacks Investment Research. View article details on hiswai:

Excerpt

<b>Vanguard Group</b> Inc. now owns 1,901,373 shares of the company's stock worth $20,269,000 after buying an additional 103,005 shares in the last quarter ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up